Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01038024 · ClinicalTrials.gov registry record · NA

Study for the Liquid Chromatography-mass Spectrometry (LC-MS/MS) Assessment of Oxidative DNA Damage in Relation to Antioxidant Usage

A NA study of Cancer, sponsored by Roswell Park Cancer Institute.

Completed
Registry status
NA
Development phase
38
Enrollment target
1
Study location

NCT01038024 is a NA study of Cancer that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 38 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01038024, a NA study of Cancer, has completed, sponsored by Roswell Park Cancer Institute.

COMPLETED
Registry status
NA
Development phase
38 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to evaluate the basis for the reported good effects of antioxidant supplementation. A blood test using Mass Spectrometry will measure DNA damage which is expected to decrease with antioxidant administration and therefore decrease the risk of cancer.

Conditions Studied

Interventions

  • DIETARY_SUPPLEMENT 1 tablet composed of antioxidants and minerals

Study Locations (1)

New York

  • Roswell Park Cancer Institute - Buffalo

Trial Details

FieldValue
Enrollment Target 38 participants
Start Date 2010-01
Est. Completion 2012-07
Phase NA

Sponsor

Roswell Park Cancer Institute

365 total trials

What the Registry Record Tells You About NCT01038024

The ClinicalTrials.gov registry entry for NCT01038024 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which 1 tablet composed of antioxidants and minerals is the first listed.

NCT01038024 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT01038024 about?

NCT01038024 is a clinical study titled "Study for the Liquid Chromatography-mass Spectrometry (LC-MS/MS) Assessment of Oxidative DNA Damage in Relation to Antioxidant Usage". The purpose of this study is to evaluate the basis for the reported good effects of antioxidant supplementation. A blood test using Mass Spectrometry will measure DNA damage which is expected to decrease with antioxidant administration and therefore decrease the risk of cancer.

What is the current status of trial NCT01038024?

This trial is currently completed. It is a NA study. The enrollment target is 38 participants. The study started on 2010-01. Estimated completion is 2012-07.

What conditions does trial NCT01038024 study?

This clinical trial studies the following conditions: Cancer.

What interventions are being tested in trial NCT01038024?

The interventions under investigation include: 1 tablet composed of antioxidants and minerals (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT01038024?

This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01038024 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.